Drug Profile
Pexastimogene devacirepvec - SillaJen Biotherapeutics
Alternative Names: JX-594; Pexa-Vec; TG-6006Latest Information Update: 11 Dec 2023
Price :
$50
*
At a glance
- Originator Jennerex Biotherapeutics
- Developer Bergonie Institute; Centre Leon Berard; GC Biopharma; Jennerex; Lee's Pharmaceutical; National Cancer Institute (France); National Cancer Institute (USA); Regeneron Pharmaceuticals; Royal Melbourne Hospital; SillaJen Biotherapeutics; Transgene; Yonsei University College of Medicine; Yonsei University Health System
- Class Antineoplastics; Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
- Mechanism of Action Gene transference; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Liver cancer
- Phase II Breast cancer; Prostate cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
- Phase I/II Colorectal cancer; Malignant melanoma
- Preclinical Gastric cancer
- No development reported Ovarian cancer; Pancreatic cancer
Most Recent Events
- 20 Oct 2023 Efficacy and adverse events data from a phase I/II trial in Renal cell carcinoma presented at the 48th European Society for Medical Oncology Congress (ESMO-2023)
- 24 Jul 2023 Pexastimogene devacirepvec is still in phase I trials for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in France (Intratumoural, Injection) (NCT02977156)
- 24 Jul 2023 SillaJen Biotherapeutics pipeline: Updated intro, KDM, reverted NDR and frwded lines to ph-I/II in RCC; NDR reverted based on NCT mentioned in the pipeline; initiated ACTRN12620001286932 trial and completed planned trial FE